Description
Digestix – Reclaim Energy, Ease Long COVID
A Patent-Pending Exploratory IL6 Solution
Apply Coupon Code for 1-Free Trial: Try15Free | applicable once per account
Product Overview
Digestix is a patent-pending dietary supplement targeting gut-derived IL6, a key inflammation driver in Long COVID and chronic disorders like arthritis, autoimmunity, Alzheimer’s, and cancer relapse. Each serving blends 2.5g proprietary oil-sorbent coffee bean fiber, 0.75g activated charcoal, and 3g honey to:
-
Reduce Endotoxin Source: May lower fecal bacterial load, a primary producer of endotoxins linked to IL6 [1].
-
Bind Endotoxins: Coffee fiber and charcoal may reduce endotoxemia, further cutting IL6 production [1].
Formulated for those navigating persistent symptoms, Digestix explores a gut-IL6 link backed by research, not yet proven for Long COVID itself.
How to Use
-
Directions: Take 1-2 sachets before meals, twice daily.
-
Precautions: Do not use if allergic to honey or if you have obstructive bowel disorders (e.g., bowel obstruction). Consult a healthcare provider if unsure.
The Long COVID Connection
Long COVID—fatigue, brain fog, and pain lingering beyond 4 weeks post-infection [2]—is tied to elevated IL6, often from gut endotoxemia [3, 4]. IL6 also fuels chronic conditions like rheumatoid arthritis, Alzheimer’s progression, and cancer relapse [5, 8-10]. No proven treatment exists, but studies show dietary fiber can cut IL6 via endotoxin reduction [6]. Digestix builds on this science—with a caveat: it lacks direct clinical trials for Long COVID or these disorders. These statements are not FDA-evaluated; Digestix isn’t intended to diagnose, treat, cure, or prevent any disease.
Our Science-Driven Mission
Inspired by fiber’s IL6-lowering potential [6, 7], Digestix tests a novel approach to gut-driven inflammation [1]. It’s exploratory—not a cure. We’re committed to clinical trials to assess its benefits for Long COVID, cancer, and other high-IL6 states. Your involvement helps us push this research forward.
Pricing & Trial Offer
-
1-Week Free Trial with 15 Sachets (Coupon – Try15Free): Just $34 shipping from Singapore (covers international delivery). No subscriptions, no commitments. Limited to one trial per account; Xylonix reserves the right to refuse orders deemed abusive.
-
1-Month Supply (60 Sachets): $140, free shipping—for those who find it helpful. Limited to 2 orders per month due to small supply.
Available in the US and Australia.
Join the Exploration
Digestix offers a low-risk way to explore relief from Long COVID or IL6-related conditions. Together, let’s navigate the Long COVID challenge. Your trial supports our Long COVID and cancer research—try it, share your experience, and help shape the future of chronic wellness!
References
[1] Cani, P. D., et al. (2007). Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes. doi:10.2337/db06-1491
[2] Crook, H., et al. (2021). Long covid—mechanisms, risk factors, and management. BMJ. doi:10.1136/bmj.n1648
[3] Sirivongrangson, P., et al. (2020). Endotoxemia and circulating bacteriome in severe COVID-19 patients. Intensive Care Med Exp. doi:10.1186/s40635-020-00362-8
[4] Kruglikov, I. L., & Scherer, P. E. (2021). Preexisting and inducible endotoxemia as crucial contributors to the severity of COVID-19 outcomes. PLOS Pathogens. doi:10.1371/journal.ppat.1009306
[5] Rose-John, S. (2012). IL-6 trans-signaling via the soluble IL-6 receptor. Int J Biol Sci. doi:10.7150/ijbs.4989
[6] Ranneh, Y., et al. (2023). Effect of dietary fiber supplementation on metabolic endotoxemia. Methods Protoc. doi:10.3390/mps6050084
[7] Brown, B. I. (2017). Nutritional management of metabolic endotoxemia. Altern Ther Health Med.
[8] Dantzer, R., et al. (2008). From inflammation to sickness and depression. Nat Rev Neurosci. doi:10.1038/nrn2297
[9] Ridker, P. M., et al. (2018). Anti-inflammatory therapy with canakinumab. N Engl J Med. doi:10.1056/NEJMoa1707914
[10] Grivennikov, S. I., & Karin, M. (2011). Inflammatory cytokines in cancer. Ann Rheum Dis. doi:10.1136/ard.2010.140145
[2] Crook, H., et al. (2021). Long covid—mechanisms, risk factors, and management. BMJ. doi:10.1136/bmj.n1648
[3] Sirivongrangson, P., et al. (2020). Endotoxemia and circulating bacteriome in severe COVID-19 patients. Intensive Care Med Exp. doi:10.1186/s40635-020-00362-8
[4] Kruglikov, I. L., & Scherer, P. E. (2021). Preexisting and inducible endotoxemia as crucial contributors to the severity of COVID-19 outcomes. PLOS Pathogens. doi:10.1371/journal.ppat.1009306
[5] Rose-John, S. (2012). IL-6 trans-signaling via the soluble IL-6 receptor. Int J Biol Sci. doi:10.7150/ijbs.4989
[6] Ranneh, Y., et al. (2023). Effect of dietary fiber supplementation on metabolic endotoxemia. Methods Protoc. doi:10.3390/mps6050084
[7] Brown, B. I. (2017). Nutritional management of metabolic endotoxemia. Altern Ther Health Med.
[8] Dantzer, R., et al. (2008). From inflammation to sickness and depression. Nat Rev Neurosci. doi:10.1038/nrn2297
[9] Ridker, P. M., et al. (2018). Anti-inflammatory therapy with canakinumab. N Engl J Med. doi:10.1056/NEJMoa1707914
[10] Grivennikov, S. I., & Karin, M. (2011). Inflammatory cytokines in cancer. Ann Rheum Dis. doi:10.1136/ard.2010.140145
Reviews
There are no reviews yet.